|
|
|
 |
Search published articles |
 |
|
Showing 2 results for Subject: Immunology
Leili Aghebati-Maleki, Ali Aghebati-Maleki, Ali Fotouhi, Sanam Nami,
Volume 21, Issue 3 (10-2021)
Abstract
Candida albicans is the most common cause of invasive candidiasis, but in recent years the incidence of infections caused by other species such as Candida Kruzei, Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida lusitania has increased. In the last decade, the treatment methods for invasive candidiasis have changed completely, and a successful treatment depends on the timely start of treatment, the selection of an effective drug, and the lack of resistance of the fungus to that particular drug. On the other hand, the widespread use of immunosuppressive drugs as well as organ transplants has all caused widespread problems in the treatment of invasive candidiasis. Together, these observations highlight a rationale for the immediate development of new immunotherapy methods to enhance antifungal therapy in immunocompromised hosts. The past decade has seen great advances in our understanding of fungal immunobiology, leading to a number of new molecular and cellular immunotherapy methods for invasive fungal infections. Therefore, the aim of this study was to review the common and new antifungal drugs in the treatment of invasive candidiasis and to discuss the role of immunotherapy in better prevention and control of the disease.
Narges Khaghanzadeh, Fatemeh Javadi, Afshin Samiei,
Volume 24, Issue 2 (7-2024)
Abstract
Leishmaniasis is a parasitic infectious disease that accounts for approximately one million new cases annually. The treatment of this disease is complex and costly, particularly in developing countries. Numerous studies have been conducted on various vaccines utilizing live attenuated parasites, killed parasites, subunit antigens, recombinant vaccines, and DNA technology. However, an effective and widely applicable preventive vaccine for leishmaniasis has not yet been developed. Present study aimed to examine the progress in the development of leishmaniasis vaccines.
Articles for this study were selected from the PubMed, Web of Science and Scopus databases using relevant keywords, focusing on subject matter, scientific quality, and publication date, with an emphasis on more recent publications.
Research on the development of leishmaniasis vaccines indicates that several candidates, such as Leishmune, CaniLeish, and Leish-Tec, which are at various stages of clinical trials, may serve as suitable options for controlling and preventing leishmaniasis in dogs. The LeishChim vaccine, designed using immunoinformatics and molecular docking techniques, has shown promising efficacy results in mouse studies. Additionally, the mutant gene-centered LmCen-/- vaccine has completed Phase 1 clinical trials in humans.
Given the importance of developing a leishmaniasis vaccine, research in this area continues. Utilizing immunoinformatics and biological modeling studies can aid in the faster identification of effective vaccine candidates.
|
|
.png)
.png)
